Gujarat Kidney’s fresh public issue sparked noticeable interest on its first bidding day, especially from retail investors.
IPO Subscription Overview
By the end of Day 1 (Dec 22), the issue received bids for 2.02 crore shares against an offer of 1.32 crore shares, giving an overall subscription of 1.53 times.
- Retail individual investors: 5.06× subscription
- Non‑institutional buyers: 1.97× subscription
- Qualified Institutional Buyers (QIB): 0.34× subscription
Key Details of the Issue
The company is raising ₹250.80 crore through a book‑built issue of 2.20 crore fresh shares. The price band is set at ₹108 – ₹114 per share.
- Minimum lot size: 128 shares
- Maximum allocation: 13 lots per investor
- At the top of the band (₹114), the smallest retail investment is ₹14,592 per lot
Allotment Timeline
- Allotment result: expected on Friday, Dec 26
- Refunds start: Monday, Dec 29
- Shares credited to demat accounts: same day as refunds
- Listing on NSE & BSE (tentative): Tuesday, Dec 30
Grey Market Premium Insight
As of today, the grey market premium (GMP) is around ₹7 per share, hinting at a potential listing price near ₹121 – roughly a 6% premium over the issue’s top price. While GMP can give an early sense of market sentiment, it should not be the sole basis for investment decisions.
About Gujarat Kidney
Gujarat Kidney operates a network of mid‑size multi‑specialty hospitals in central Gujarat, focusing on secondary and tertiary care. The consolidated group runs:
- 7 multispecialty hospitals
- 4 pharmacies
- 490 total beds (operational capacity of 340 beds)
The company aims to expand its footprint while delivering integrated healthcare services.
Remember, this is perspective, not a prediction. Do your own research and consult certified experts before making any investment decisions.